Evaluation of Efficacy and Mechs of Topical Thalidomide

这项随机对照临床试验的目的是通过测试一种新的局部肿瘤坏死因子(TNF)- α调节剂沙利度胺与安慰剂对慢性移植物抗宿主病（cGVHD）相关口炎的作用，阐明炎症在慢性移植物抗宿主病（cGVHD）相关口炎中的作用。本研究的具体目的是：1)评价局部应用沙利度胺治疗cgvhd相关性口腔炎的临床疗效；2)评估外用沙利度胺治疗cgvhd相关性口腔炎的安全性和耐受性；3)利用局部应用沙利度胺作为药理学工具，研究炎症在cGVHD相关口炎中的作用。我们的总体假设是，细胞因子tnf - α通过局部炎症反应在cgvhd相关口炎的发病机制中起主要作用，局部应用假定的tnf - α调节剂沙利度胺可以改善炎症反应。该研究计划测试局部沙利度胺与安慰剂在膏状制剂（N = 66）和漱口剂制剂（N = 66）中的有效性。纳入标准包括年龄在18至80岁之间，经手术活检结果证实诊断为口腔cGVHD的患者。

The purpose of this randomized controlled clinical trial is to elucidate the role of inflammation in chronic graft-versus-host-disease (cGVHD)-related stomatitis by testing the effects of a novel topical tumor necrosis factor (TNF)-alpha modulator, thalidomide, versus placebo for this oral condition. The specific aims of this study are the following: 1) to assess the clinical efficacy of topical thalidomide for treatment of cGVHD-related stomatitis; 2) to assess the safety and tolerability of topical thalidomide for the treatment of cGVHD-related stomatitis; and 3) to examine the role of inflammation in cGVHD related stomatitis using topically applied thalidomide as a pharmacologic tool. Our overall hypothesis is that the cytokine TNF-alpha plays a major role in the pathogenesis of cGVHD-related stomatitis via the local inflammatory response, which is modified by the topical application of the putative TNF-alpha modulator, thalidomide. The study is planned to test the effectiveness of topical thalidomide versus placebo in a paste formulation (N = 66), and also in a mouthwash formulation (N = 66). Inclusion criteria include patients between the ages of 18 and 80 who have a diagnosis of oral cGVHD as confirmed by surgical biopsy results. The study will begin to accrue subjects following the approval of the protocol data and safety monitoring plan by the Data and Safety Monitoring Board, which convened in August, 2005. In addition to the patient population provided by Richard Childs, MD, Associate Investigator, National Heart, Lung, and Blood Institute, cGVHD patients may be referred through the weekly National Cancer Institute sponsored cGVHD Clinic at the Clinical Center, National Institutes of Health (NIH), as well as through the National Cancer Institute-sponsored cGVHD natural history protocol "Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients with cGVHD" (04-C-0281). Topical thalidomide is prepared by the Pharmaceutical Development Service, Clinical Center, NIH. The IRB was informed on September 20, 2004 that the protocol was transferred from the National Insitute of Dental and Craniofacial Research to the National Institute of Nursing Research.